BUZZ-Revolution Medicines rises after pancreatic cancer drug doubles survival in study

Revolution Medicines

Revolution Medicines

RVMD

0.00

** Shares of biotech Revolution Medicines RVMD.O rise 8.7% to $171.22 premarket

** In a 500-patient late-stage trial, experimental pancreatic cancer drug daraxonrasib doubled survival, compared with chemotherapy, and improved symptoms enough that some patients could resume activities they had previously abandoned

** In patients with advanced pancreatic cancer who had failed one round of chemotherapy, the once-daily pill daraxonrasib cut the risk of death by 60% compared with standard chemotherapy

** As of last close, RVMD stock was up over 97% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.